Recent work from our group has demonstrated that combination therapy of paricalcitol and enalapril improved renal function and histology, suppressing the progression of renal failure via mediation/inhibition of the TGFβ-1 signaling pathway [7, 18, 19]. This evidence concerns the gene TGFB1 and acute kidney injury.